CALC – calcimedica, inc. (US:NASDAQ)

News

CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com